Recombinant multi-species ARID1B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ARID1B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This locus encodes an AT-rich DNA interacting domain-containing protein. The encoded protein is a component of the SWI/SNF chromatin remodeling complex and may play a role in cell-cycle activation. The protein encoded by this locus is similar to AT-rich interactive domain-containing protein 1A. These two proteins function as alternative, mutually exclusive ARID-subunits of the SWI/SNF complex. The associated complexes play opposing roles. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2016]
The Alternative Names of target: 6A3-5,8030481M12,9330189K18Rik,ARID domain-containing protein 1B,ARID1B,AT-rich interactive domain-containing protein 1B,Ardi1b,Arid1b,B230217J03Rik,BAF250B,BRG1-associated factor 250b (BAF250B),BRG1-binding protein hELD/OSA1,BRIGHT,CSS1,DAN15,ELD/OSA1,MRD12,OSA2,Osa homolog 2 (hOsa2),P250R,SMARCF2,Smcf1,mKIAA1235,p250R,smcf-1

Target products collectionGo to ARID1B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP10619-Ag-1/ GM-Tg-hg-IP10619-Ag-2 Human ARID1B protein Human
GM-Tg-rg-IP10619-Ag-1/ GM-Tg-rg-IP10619-Ag-2 Rat ARID1B protein Rat
GM-Tg-mg-IP10619-Ag-1/ GM-Tg-mg-IP10619-Ag-2 Mouse ARID1B protein Mouse
GM-Tg-cynog-IP10619-Ag-1/ GM-Tg-cynog-IP10619-Ag-2 Cynomolgus/Rhesus macaque ARID1B protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP10619-Ag-1/ GM-Tg-felg-IP10619-Ag-2 Feline ARID1B protein Feline
GM-Tg-cang-IP10619-Ag-1/ GM-Tg-cang-IP10619-Ag-2 Canine ARID1B protein Canine
GM-Tg-bovg-IP10619-Ag-1/ GM-Tg-bovg-IP10619-Ag-2 Bovine ARID1B protein Bovine
GM-Tg-equg-IP10619-Ag-1/ GM-Tg-equg-IP10619-Ag-2 Equine ARID1B protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP10619-Ag-1/ GM-Tg-hg-IP10619-Ag-2; GM-Tg-rg-IP10619-Ag-1/ GM-Tg-rg-IP10619-Ag-2;
GM-Tg-mg-IP10619-Ag-1/ GM-Tg-mg-IP10619-Ag-2; GM-Tg-cynog-IP10619-Ag-1/ GM-Tg-cynog-IP10619-Ag-2;
GM-Tg-felg-IP10619-Ag-1/ GM-Tg-felg-IP10619-Ag-2; GM-Tg-cang-IP10619-Ag-1/ GM-Tg-cang-IP10619-Ag-2;
GM-Tg-bovg-IP10619-Ag-1/ GM-Tg-bovg-IP10619-Ag-2; GM-Tg-equg-IP10619-Ag-1/ GM-Tg-equg-IP10619-Ag-2
Products Name ARID1B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name ARID1B
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ARID1B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.